We are live on ! Find out more
VIRS

Pacer BioThreat Strategy ETF
VIRS

Delisted

VIRS was delisted on the 10th of October, 2024.

Back to rankings

4 hedge funds and large institutions have $1.71M invested in Pacer BioThreat Strategy ETF in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

47% more capital invested

Capital invested by funds: $1.16M → $1.71M (+$547K)

33% more funds holding

Funds holding: 3 → 4 (+1)

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$529K
2
Osaic Holdings
Osaic Holdings
Arizona
+$3.85K

Top Sellers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$49.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
1
Royal Bank of Canada
Ontario, Canada
$1.36M +$529K +18,276 +64%
Cambridge Investment Research Advisors
2
Cambridge Investment Research Advisors
Iowa
$272K -$49.4K -1,708 -15%
Osaic Holdings
3
Osaic Holdings
Arizona
$56K +$3.85K +133 +7%
HI
4
Harbour Investments
Wisconsin
$18K +$17.6K +608 New

VIRS Hedge Fund Activity: Q1 2021 in Review

4 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Pacer BioThreat Strategy ETF (VIRS) for Q1 2021, worth a combined $1.71M — up 47% from $1.16M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new VIRS positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Royal Bank of Canada, adding an estimated $529K. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $49.4K.

  • 4 institutional investors held Pacer BioThreat Strategy ETF (VIRS) as of Q1 2021, up from 3 in Q4 2020.
  • Funds reported $1.71M of Pacer BioThreat Strategy ETF stock for Q1 2021, up 47% quarter-over-quarter.
  • 1 fund opened new Pacer BioThreat Strategy ETF positions in Q1 2021 and 0 closed out, a net change of +1 holder.
  • The largest Pacer BioThreat Strategy ETF buyer in Q1 2021 was Royal Bank of Canada, an estimated $529K added.
  • The largest Pacer BioThreat Strategy ETF seller in Q1 2021 was Cambridge Investment Research Advisors, an estimated $49.4K sold.

Based on aggregated 13F filings for Q1 2021.